Hepatology

A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

In this placebo-controlled, randomized trial of pioglitazone in subjects with nonalcoholic steatohepatitis, pioglitazone was associated with improvements in the results of liver-function tests, hepatic fat content, and hepatic insulin sensitivity. As compared with placebo, pioglitazone significantly reduced the histologic abnormalities of steatohepatitis but did not significantly reduce fibrosis.
Read more

 http://content.nejm.org/cgi/content/short/355/22/2297?rss=1&...

New England Journal of Medicine